Drug Trial Radar · NCT00477295
A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy
Last checked: Nov 20, 2026Latest source record: Dec 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
583
Actual
Start
May 2007
Primary completion
Dec 2010
Study completion Jan 2011
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- May 23, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-arm, randomized, double-blind, non-inferiority study using a flexible dosing regime to allow optimal zonisamide or carbamazepine therapy for individual subjects. Assessment of eligibility will take place at the Screening Visit. The subjects will be randomized to either the carbamazepine or zonisamide arm at the Randomization Visit (T1). T1 must occur as soon as possible (and at least within 14 days) of the Screening Visit in order to optimize subject care.
Conditions
- Epilepsy
Interventions
ZonisamideDrug
Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
CarbamazepineDrug
Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experienced Seizure Freedom for 26-weeks During the Maintenance PhaseTime frame: Week 31 through Week 109
Locations
79 sites in 18 countries. Site status is shown where the registry gives one.
Site not named
Camperdown, Australia
Site not named
Clayton, Australia
Site not named
Fitzroy, Australia
Site not named
Flinders, Australia
Site not named
Heidelberg West, Australia
Site not named
Parkville, Australia
Site not named
Queensland, Australia
Site not named
Wellington, Australia
Site not named
Aalborg, Denmark
Site not named
Béthune, France
Site not named
Dijon, France
Site not named
Paris, France
Site not named
Saint-Etienne, France
Site not named
Berlin, Germany
Site not named
Bochum, Germany
Site not named
Düsseldorf, Germany
Site not named
Munich, Germany
Site not named
Schwerin, Germany
Site not named
Westerstede, Germany
Site not named
Athens, Greece
Site not named
Thessaloniki, Greece
Site not named
Budapest, Hungary
Site not named
Debrecen, Hungary
Site not named
Gyula, Hungary
Site not named
Hódmezővásárhely, Hungary
Site not named
Nyregyhaza, Hungary
Site not named
Zalaegerszeg-Pozva, Hungary
Site not named
Bangalore, India
Site not named
Hyderabad, India
Site not named
Koturpuram, India
Site not named
Madurai, India
Site not named
New Delhi, India
Site not named
Pune, India
Site not named
Milan, Italy
Site not named
Monza, Italy
Site not named
Orbassano, Italy
Site not named
Rome, Italy
Site not named
Gdansk, Poland
Site not named
Katowice, Poland
Site not named
Krakow, Poland
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.